Summary
Pfizer Inc.'s 2010 10-K report highlights a strong year, driven significantly by the integration of Wyeth acquired in late 2009. The company reported substantial revenue growth, largely attributed to the inclusion of Wyeth's operational revenues, particularly within the Biopharmaceutical segment which constitutes the majority of Pfizer's business. Key therapeutic areas for growth and focus include immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience, and vaccines. The company is navigating a complex regulatory and competitive landscape, with ongoing patent expirations and the increasing threat of generic competition for major products like Lipitor. Despite these challenges, Pfizer is actively managing its product portfolio and R&D pipeline, with a stated focus on fewer, higher-impact disease areas to optimize future growth. The acquisition of King Pharmaceuticals in early 2011 further signals strategic moves to bolster its market position. Investors should note the significant R&D investments and the company's commitment to innovation, balanced against efforts to control costs and adapt to evolving healthcare policies, such as the U.S. Affordable Care Act.
Financial Highlights
51 data points| Revenue | $65.17B |
| Cost of Revenue | $14.79B |
| Gross Profit | $50.38B |
| SG&A Expenses | $18.97B |
| Operating Income | $8.29B |
| Interest Expense | $1.80B |
| Net Income | $8.26B |
| EPS (Basic) | $1.03 |
| EPS (Diluted) | $1.02 |
| Shares Outstanding (Basic) | 8.04B |
| Shares Outstanding (Diluted) | 8.07B |
Key Highlights
- 1Significant revenue growth in 2010, largely due to the acquisition of Wyeth, boosting the Biopharmaceutical segment's performance.
- 2The Biopharmaceutical segment represented approximately 86% of total revenues in 2010, underscoring its strategic importance.
- 3Pfizer is strategically focusing its research and development efforts on high-priority therapeutic areas: immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain, and vaccines.
- 4Key products like Lipitor, Enbrel, Lyrica, and Prevnar/Prevenar 13 continue to be significant revenue drivers, though patent expirations for major drugs like Lipitor pose future challenges.
- 5The company is actively managing its real estate portfolio, consolidating operations and reducing its overall operational footprint.
- 6Acquisition of King Pharmaceuticals completed in January 2011, following the significant Wyeth acquisition in late 2009, indicating a strategy of growth through M&A.
- 7Pfizer is actively addressing the risks associated with patent expirations and generic competition through ongoing patent challenges and strategic business development.